Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Martha Wadleigh, Paul G. Richardson, David Zahrieh, Stephanie J. Lee, Corey Cutler, Vincent Ho, Edwin P. Alyea, Joseph H. Antin, Richard M. Stone, Robert J. Soiffer, Daniel J. DeAngelo

Research output: Contribution to journal › Article › peer-review

243 Scopus citations

Fingerprint

Dive into the research topics of 'Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds